Transgene Biotek Share Price Today | Stock Price & Transgene Biotek Share Screener
As of October 5, 2026, the live Transgene Biotek share price (BSE: TRABI) is ₹2.43, up 1.25% from the previous close, with shares trading between ₹2.35 and ₹2.47 in today's trading session, and a 52-week range of ₹1.97–₹4.28. Check TRABI 52-week performance for the annual price range and momentum. Use the Transgene Biotek stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Transgene Biotek opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Transgene Biotek Share Price Chart
Track the current stock price of Transgene Biotek with an interactive chart. Analyse TRABI share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Transgene Biotek stock quote in one place.
The quote of ₹2.43 sits between the 52-week low of ₹1.97 and the 52-week high of ₹4.28, and the latest session moved 1.25% from the previous close.
Transgene Biotek Company Profile - Fundamental Screener
Screen Transgene Biotek company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for TRABI shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare Services sector and the Healthcare Service Provider industry, and it trades under ISIN INE773D01018.
Company Details
Classification
Identifiers and Leadership
Transgene Biotek Balance Sheet Screener
Screen TRABI balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹144, down from ₹144 in 2025.
Latest statistics put total assets at ₹144 and shareholder funds at ₹8, with a leverage ratio of 1.38.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 144 | 144 | 142 | 142 | 147 | 157 | 167 | 177 | 187 | 198 |
| Current Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Fixed Assets | 10 | 8 | 6 | 6 | 11 | 21 | 31 | 41 | 51 | 61 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 122 | 121 | 121 | 121 | 121 | 121 | 120 | 120 | 120 | 128 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 8 | 10 | 11 | 11 | 17 | 22 | 33 | 44 | 52 | 59 |
| Share Capital | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 |
| Reserves & Surplus | -67 | -66 | -65 | -64 | -58 | -54 | -43 | -32 | -23 | -17 |
Transgene Biotek Income Statement Screener - Profit & Revenue Analysis
Screen Transgene Biotek income statement and profit fundamentals. Analyze TRABI quarterly results. Transgene Biotek reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹0 and net profit was ₹-1, equal to earnings per unit of ₹-0.06, at an operating margin of -560%.
In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹0 and net profit of ₹0.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit % | -560.00% | -100.00% | -675.00% | -280.00% | -160.00% | -120.00% | -520.00% | -820.00% | -133.00% | -113.00% | 0.00% | -120.00% | -240.00% | -200.00% | -56.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | -1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 | -3 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 | -3 |
| EPS | -0.06 | -0.05 | -0.09 | -0.06 | -0.05 | -0.05 | -0.04 | 0.03 | -0.01 | -0.01 | -0.19 | -0.02 | -0.02 | -0.02 | -0.34 |
Transgene Biotek Cash Flow Screener - Liquidity Fundamentals
Screen TRABI cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹1.
Over the same period, investing activities used ₹2 and financing activities provided ₹1.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 1 | 0 | 0 | 0 | 0 | 0 | -2 | -1 | 0 | 7 |
| Investing Activities | -2 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | -7 |
Financing and Net Cash | ||||||||||
| Financing Activities | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Transgene Biotek Shareholding Pattern Screener
See Transgene Biotek shareholding pattern with promoter, FII, and DII holdings. Check Transgene Biotek promoter holding and ownership changes for TRABI on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 23.64%, foreign institutions 0.00%, domestic institutions 0.00% and the public 71.81%, spread across 13,767 shareholders.
The shareholder count was 13,767 in 2026-Mar, compared with 13,817 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 71.81% | 71.70% | 71.88% | 71.89% | 71.85% | 71.85% | 71.45% | 71.75% |
| Other Holding | 4.55% | 4.66% | 4.48% | 4.48% | 4.51% | 4.51% | 4.92% | 4.61% |
| Shareholder Count | 13,767 | 13,817 | 13,583 | 13,475 | 13,461 | 13,545 | 12,426 | 12,766 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Transgene Biotek. Transgene Biotek dividend yield can be compared with peers and other stocks in the market.
Transgene Biotek Stock Index Membership - Nifty & Sensex
See which indices include Transgene Biotek stock. Check TRABI index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Transgene Biotek Market Events Screener - Corporate Actions
Get Transgene Biotek corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Transgene Biotek stock events that may affect TRABI share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Annual General Meeting dated December 30, 2026, with a record date of December 30, 2026.
It is followed by Quarterly Result Announcement dated August 7, 2026 and Quarterly Result Announcement dated May 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-12-30 | 2026-12-30 | Annual General Meeting | NA | -28.21% |
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | -2.35% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 3.22% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 16.36% |
| 2025-12-07 | 2025-12-07 | Extraordinary General Meeting | NA | 0.00% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 4.28% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | 2.14% |
| 2025-05-07 | 2025-05-07 | Quarterly Result Announcement | NA | -10.03% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | 4.20% |
| 2024-12-05 | 2024-12-05 | Annual General Meeting | NA | 0.74% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -3.82% |
| 2023-12-30 | 2023-12-30 | Annual General Meeting | NA | 58.94% |
Transgene Biotek Competitors Screener - Peer Stocks Comparison
Screen TRABI competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare Services sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 33,655 | 61.65 | 2,864 | 12.11% | 510 | 67.22 |
| Vijaya Diagnostic Centre | 14,708 | 78.49 | 835 | 19.34% | 173 | 41.15 |
| Metropolis Healthcare | 11,155 | 55.01 | 1,671 | 24.15% | 191 | 32.15 |
| Thyrocare Technologies | 8,493 | 48.36 | 846 | 20.48% | 163 | 36.09 |
| Nephrocare Health Services | 6,526 | 76.48 | 1,023 | 32.93% | 77 | 32.49 |
| Suraksha Diagnostic | 1,824 | 52.04 | 314 | 22.55% | 31 | 61.14 |
| Krsnaa Diagnostics | 1,800 | 18.46 | 816 | 9.90% | 101 | 51.22 |
| 3B BlackBio DX | 1,413 | 25.24 | 142 | 27.17% | 61 | 65.96 |
| One Global Service Provider | 1,027 | 13.95 | 499 | 237.48% | 70 | 42.95 |
| Health X Platform | 868 | -33.43 | 1,378 | 17.65% | -1 | 29.80 |
Transgene Biotek Company Announcements - News & Reports Screener
Screen TRABI latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 4, 2026.
The next most recent announcements are dated October 4, 2026 and October 4, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-04 | Reg. 32(1) Statement Of Deviation & Variation. | - |
| 2026-10-04 | Compliance-57 (5) : intimation after the end of quarter | - |
| 2026-10-04 | Compliance-57 (4) : Prior intimation to the beginning of the quarter | - |
| 2026-10-04 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-10-04 | Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-10-04 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-03 | Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-26 | Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 We Wish To Inform You That The Company Has Received Approval From The Registrar Of Companies (ROC) Hyderabad Telangana For Extension Of Time For Holdi | - |
| 2026-09-23 | Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors | - |
| 2026-09-22 | Closure of Trading Window | - |
| 2026-09-22 | Closure of Trading Window | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-07 | 1)The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026. 2) The Board Considered And Approved The Limited Review Report (Standalone & Consolidated) Of The Compa | - |
| 2026-08-07 | Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 07 2026. | - |
| 2026-07-23 | Board Meeting Intimation for Intimation Of The Board Meeting. | - |
| 2026-07-22 | Compliance-57 (4) : Prior intimation to the beginning of the quarter | - |
| 2026-07-22 | Statement Of Deviation & Variation | - |
| 2026-07-22 | Compliance-57 (5) : intimation after the end of quarter | - |
| 2026-07-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-20 | Closure of Trading Window | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹2.43, within a 52-week range of ₹1.97 to ₹4.28. The P/E ratio is -11.43 and the P/B ratio is 2.17, with earnings per unit of ₹-0.22. Market capitalisation stands at ₹18.20 Cr. The company operates in the Healthcare Services sector, in the Healthcare Service Provider industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.